- Home
- KRG vs KRYS Comparison
KRG vs KRYS Comparison
Compare KRG & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRG
- KRYS
- Stock Information
- Founded
- KRG 1971
- KRYS 2015
- Country
- KRG United States
- KRYS United States
- Employees
- KRG N/A
- KRYS N/A
- Industry
- KRG Real Estate Investment Trusts
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KRG Real Estate
- KRYS Health Care
- Exchange
- KRG Nasdaq
- KRYS Nasdaq
- Market Cap
- KRG 5.0B
- KRYS 4.3B
- IPO Year
- KRG 2004
- KRYS 2017
- Fundamental
- Price
- KRG $22.77
- KRYS $150.49
- Analyst Decision
- KRG Buy
- KRYS Strong Buy
- Analyst Count
- KRG 8
- KRYS 10
- Target Price
- KRG $27.13
- KRYS $204.90
- AVG Volume (30 Days)
- KRG 1.8M
- KRYS 422.6K
- Earning Date
- KRG 07-30-2025
- KRYS 08-04-2025
- Dividend Yield
- KRG 4.75%
- KRYS N/A
- EPS Growth
- KRG N/A
- KRYS 36.22
- EPS
- KRG 0.79
- KRYS 4.91
- Revenue
- KRG $857,126,000.00
- KRYS $359,205,000.00
- Revenue This Year
- KRG $3.42
- KRYS $34.33
- Revenue Next Year
- KRG $2.94
- KRYS $47.84
- P/E Ratio
- KRG $28.97
- KRYS $30.77
- Revenue Growth
- KRG 3.60
- KRYS 116.08
- 52 Week Low
- KRG $18.52
- KRYS $122.80
- 52 Week High
- KRG $28.24
- KRYS $207.84
- Technical
- Relative Strength Index (RSI)
- KRG 59.60
- KRYS 56.41
- Support Level
- KRG $21.76
- KRYS $142.51
- Resistance Level
- KRG $22.28
- KRYS $147.58
- Average True Range (ATR)
- KRG 0.47
- KRYS 4.78
- MACD
- KRG 0.13
- KRYS 0.39
- Stochastic Oscillator
- KRG 95.98
- KRYS 92.81
About KRG Kite Realty Group Trust
Kite Realty Group Trust specializes in owning, operating, acquiring, developing, and redeveloping high-quality open-air shopping centers and mixed-use assets. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.